AKB-9778: Phase Ib/IIa started

Aerpio began a 28-day, U.S. Phase Ib/IIa trial to evaluate ascending doses of AKB-9778 in up to 24 patients. In January, Akebia Therapeutics Inc. (Cincinnati, Ohio) spun out Aerpio to focus on diabet...